AJ Abarca, CFA

AGS Therapeutics, based in Paris and Genopole (www.genopole.fr), Evry, France, is a biotech company pioneering the use of microalgae extracellular vesicles (MEVs) as a universal delivery system for innovative biologics, vaccines and gene therapies. AGS has shown MEVs to be a safe, targeted and highly versatile delivery system for mRNA, siRNA, DNA oligos, plasmids, proteins, and peptides relevant to a broad range of human diseases. AGS Therapeutics has two lead therapeutic candidates in development, both addressing multi-billion markets with significant unmet needs: • AGS-1010 for wet age-related macular degeneration (wAMD), with a potential breakthrough in topical administration (eye drops) that could significantly improve patient comfort and compliance compared to current standard-of-care (injections into the eye). • AGS-2010 for inflammatory bowel disease (IBD), offering a non-systemic oral treatment option. AGS-M, the company’s CDMO subsidiary, produces the MEVs needed to support R&D from AGS and from companies partnering with AGS. AGS’ MEVs are derived from Chlorella, a two-billion-year-old single-cell algae, labelled by the FDA as GRAS for consumption as a food supplement. AGS’ MEVs are easy to manufacture in large quantities with processes that are both eco-friendly and easily scalable. Through strategic partnerships and a commitment to scientific excellence, the company aims to challAGS-M, a contract development and manufacturing organization, produces the MEVs needed to support preclinical and clinical development of MEV-based product pipelines from AGS Therapeutics, and from pharmaceutical and other companies partnering with AGS. AGS’ MEVs are derived from Chlorella, a 2-billion-year-old single-cell algae used for decades as a food supplement. AGS’ MEVs are easy to manufacture in large quantities with simple cell culture media production techniques that are both eco-friendly and easily scalable. For more information visit www.ags-tx.com and www.ags-m.com.

Our vision is to connect food-lovers through a unique gourmet experience without the premium cost of an upscale restaurant. By focusing on food and quality, icook provides chefs with a platform to market their culinary talent to the world.

Chintai is a leading one-stop solution for modernising capital markets. Regulated and licenced by the Monetary Authority of Singapore, the Chintai platform uses blockchain technology to enable traditional finance and innovative companies to harness the power of digital assets. Gain access to a robust automated compliance engine powered by Chintais proprietary Sentinel-AI technology with an end-to-end white labelling solution. The product suite includes all features and functionalities to streamline business operations and create a competitive advantage for enterprises. This includes dynamic security token issuance, high-performance secondary trading and automated compliance infrastructure for regulated digital assets. The strategic aim is to bridge the gap between businesses and compliant blockchain technology with a Blockchain Platform-as-a-Service (BPaaS) model. We are regulated by the Monetary Authority of Singapore as a Capital Markets Services licensee for dealing in Capital Markets Products and a Recognised Market Operator. chintai.io - Leading businesses into the regulated digital assets frontier

TipHaus saves restaurant and hospitality managers time, money, and headaches by automating service employees tip and wage distribution. Our award-winning SaaS is the most customizable and user-friendly way for the service industry to handle tip sharing, tip pooling, letting managers worry about running their business and not manually entering data in the back office. Our first of its kind employee mobile app allows service employees to understand their finances and budget, while offering helpful tips and tricks to improve gratuities. With TipHaus, the average restaurant saves $619 per month and 10 hours of managerial time, and also: - Reduces your organizations legal liability from wage disputes - Reduces manager to employee misunderstandings.

HoneyB is the first platform that unlocks institutional-grade fixed-income yields for native Bitcoin - no wrapping, no bridging, no custody compromise. We provide bespoke asset management that seamlessly connects the multi-trillion-dollar fixed income markets to institutional BTC.

Chiron Capital seeks to support exceptional MVP through Series-C stage startups holistically, empowering its partners via bespoke solutions combining the and providing all necessary resources, both capital and non-monetary, prerequisite to a founders pursuit of success.

AGS Therapeutics, based in Paris and Genopole (www.genopole.fr), Evry, France, is a biotech company pioneering the use of microalgae extracellular vesicles (MEVs) as a universal delivery system for innovative biologics, vaccines and gene therapies. AGS has shown MEVs to be a safe, targeted and highly versatile delivery system for mRNA, siRNA, DNA oligos, plasmids, proteins, and peptides relevant to a broad range of human diseases. AGS Therapeutics has two lead therapeutic candidates in development, both addressing multi-billion markets with significant unmet needs: • AGS-1010 for wet age-related macular degeneration (wAMD), with a potential breakthrough in topical administration (eye drops) that could significantly improve patient comfort and compliance compared to current standard-of-care (injections into the eye). • AGS-2010 for inflammatory bowel disease (IBD), offering a non-systemic oral treatment option. AGS-M, the company’s CDMO subsidiary, produces the MEVs needed to support R&D from AGS and from companies partnering with AGS. AGS’ MEVs are derived from Chlorella, a two-billion-year-old single-cell algae, labelled by the FDA as GRAS for consumption as a food supplement. AGS’ MEVs are easy to manufacture in large quantities with processes that are both eco-friendly and easily scalable. Through strategic partnerships and a commitment to scientific excellence, the company aims to challAGS-M, a contract development and manufacturing organization, produces the MEVs needed to support preclinical and clinical development of MEV-based product pipelines from AGS Therapeutics, and from pharmaceutical and other companies partnering with AGS. AGS’ MEVs are derived from Chlorella, a 2-billion-year-old single-cell algae used for decades as a food supplement. AGS’ MEVs are easy to manufacture in large quantities with simple cell culture media production techniques that are both eco-friendly and easily scalable. For more information visit www.ags-tx.com and www.ags-m.com.

Our vision is to connect food-lovers through a unique gourmet experience without the premium cost of an upscale restaurant. By focusing on food and quality, icook provides chefs with a platform to market their culinary talent to the world.

Chintai is a leading one-stop solution for modernising capital markets. Regulated and licenced by the Monetary Authority of Singapore, the Chintai platform uses blockchain technology to enable traditional finance and innovative companies to harness the power of digital assets. Gain access to a robust automated compliance engine powered by Chintais proprietary Sentinel-AI technology with an end-to-end white labelling solution. The product suite includes all features and functionalities to streamline business operations and create a competitive advantage for enterprises. This includes dynamic security token issuance, high-performance secondary trading and automated compliance infrastructure for regulated digital assets. The strategic aim is to bridge the gap between businesses and compliant blockchain technology with a Blockchain Platform-as-a-Service (BPaaS) model. We are regulated by the Monetary Authority of Singapore as a Capital Markets Services licensee for dealing in Capital Markets Products and a Recognised Market Operator. chintai.io - Leading businesses into the regulated digital assets frontier